In a concerning revelation, internal records have surfaced detailing a meeting between senior officials from the Trump administration’s Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson. This encounter, held on 17 June 2025, was centered around the contentious herbicide glyphosate, a chemical at the heart of numerous lawsuits alleging its links to cancer. The meeting’s timing and content have raised alarms about the influence of corporate interests on environmental health policies.
High-Stakes Discussions at the EPA
The meeting involved key players from the EPA, including Lee Zeldin, who was the agency’s administrator at the time, along with Nancy Beck and Sean Donahue, both of whom hold significant positions within the agency. Notes from an internal email indicate that the discussions were expected to cover “litigation” and potential “supreme court action” pertaining to glyphosate. At that time, Bayer was facing mounting legal challenges, with thousands of individuals claiming their cancer diagnoses were directly linked to the use of its glyphosate-based products, such as Roundup.
Bayer’s strategy has revolved around convincing the Supreme Court that, without a mandated cancer warning from the EPA, it should not be held liable for failing to inform users about the risks associated with glyphosate. While some courts have sided with Bayer, others have rejected this argument, indicating a divided judicial perspective on the matter.
Administration’s Support for Bayer
The meeting appears to have had significant ramifications, as subsequent actions by the Trump administration exhibited a clear alignment with Bayer’s interests. Following the June meeting, the administration filed a brief with the Supreme Court advocating for Bayer’s case, and a hearing was set for 27 April. Furthermore, the White House invoked the Defense Production Act on 18 February 2026 to safeguard glyphosate production, effectively granting immunity to manufacturers like Bayer.
This shift in policy has raised eyebrows among environmental advocates. Nathan Donley, Director of Environmental Health Science at the Center for Biological Diversity, expressed concern, stating, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” Such sentiments underscore a growing apprehension about the regulatory landscape and the apparent prioritisation of corporate interests over public health.
Calls for Transparency and Accountability
Critics have underscored the imbalance in regulatory dialogue, questioning whether the EPA provides similar opportunities for advocacy groups or the individuals affected by glyphosate. Whitney Di Bona, a consumer safety advocate, highlighted the disparity: “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability,” she said, urging for equitable treatment for those who have suffered due to glyphosate exposure.
Voices from environmental activism, such as Zen Honeycutt of Moms Across America, have echoed these concerns, pointing out a troubling trend of corporate influence on regulatory bodies. “Coercion by chemical companies on our regulatory agencies is nothing new,” she remarked, emphasising the lack of meaningful action from the EPA in response to persistent calls for limiting harmful pesticides.
Why it Matters
The implications of these findings extend far beyond Bayer and glyphosate. They highlight a significant and troubling dynamic within US regulatory agencies, where corporate power appears to overshadow public health concerns. As the Biden administration seeks to rectify the environmental missteps of its predecessor, the need for transparency and accountability in the regulatory process has never been more critical. The health of countless individuals hangs in the balance, and the public deserves assurance that regulatory decisions prioritise safety over profit.
